Clinical Scorecard: Reevaluation of Cardiovascular Risk Assessment in Primary Care: Addressing SCORE2 Model Limitations
At a Glance
Category
Detail
Condition
Cardiovascular events (CVE) risk prediction
Key Mechanisms
Estimation of 10-year risk of fatal and non-fatal cardiovascular events using factors such as age, sex, smoking status, diabetes, blood pressure, and cholesterol levels
Target Population
Adults aged 40–69 years visiting general practitioners in the Netherlands for cardiovascular risk assessment
Care Setting
Primary care, general practitioner offices
Key Highlights
The SCORE2 model underestimates the 10-year risk of cardiovascular events in primary care patients, predicting 6.2% risk versus an observed 10.1%.
Underestimation occurs across sex and age groups, with observed-to-expected (O/E) risk ratios ranging from 1.54 to 1.78.
Approximately 35% of patients may miss preventive treatments due to SCORE2’s underestimation of risk.
Guideline-Based Recommendations
Diagnosis
Use SCORE2 model to estimate 10-year risk of fatal and non-fatal cardiovascular events in adults aged 40–69 years.
Consider country-specific risk calibrations when applying SCORE2 in primary care settings.
Management
Recommend preventive interventions for patients with SCORE2 risk ≥10%, or ≥7.5% for those under 50 years.
Focus on blood pressure reduction, smoking cessation, lipid lowering, weight management, and physical activity promotion.
Monitoring & Follow-up
Follow up patients regularly to reassess cardiovascular risk and treatment efficacy.
Monitor key risk factors including systolic blood pressure, cholesterol levels, smoking status, and diabetes control.
Risks
Be aware that SCORE2 may underestimate cardiovascular risk in primary care populations, potentially leading to undertreatment.
Consider additional clinical judgment or recalibration of risk models to avoid missing high-risk patients.
Patient & Prescribing Data
Adults aged 40–69 years undergoing cardiovascular risk assessment in Dutch primary care
Due to SCORE2 underestimation, a significant proportion of patients may not receive indicated preventive therapies, highlighting the need for model recalibration or supplementary risk evaluation.
Clinical Best Practices
Use SCORE2 risk estimates as part of a comprehensive cardiovascular risk assessment, not in isolation.
Consider local population data and possible model recalibration to improve risk prediction accuracy.
Engage patients in shared decision-making regarding preventive interventions based on individualized risk profiles.
Prioritize modifiable risk factors such as hypertension, smoking, diabetes, and hypercholesterolemia in management plans.
A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.